<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579344</url>
  </required_header>
  <id_info>
    <org_study_id>0528/11</org_study_id>
    <nct_id>NCT01579344</nct_id>
  </id_info>
  <brief_title>Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma</brief_title>
  <official_title>Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fabricio Lopes da Fonseca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The radioactive radioiodine therapy (Na131I) for the treatment of differentiated thyroid&#xD;
      carcinoma is a procedure used for ablation of remaining thyroid tissue after thyroidectomy&#xD;
      and metastases. Although serious complications are uncommon after treatment, there are&#xD;
      well-documented adverse reactions secondary to the involvement of the salivary glands, such&#xD;
      as dry mouth, pain in the parotid glands and dysphagia, even after administration of low&#xD;
      doses of radioiodine. However, ocular complications of such treatment are scarcely reported&#xD;
      in literature.&#xD;
&#xD;
      Among them the investigators can mention recurrent and chronic conjunctivitis,&#xD;
      keratoconjunctivitis sicca and dry eye, affecting 23% of patients undergoing radioactive&#xD;
      iodine therapy. Dysfunction of the lacrimal gland is described in recent studies, especially&#xD;
      after high cumulative dose of the drug. Likewise, epiphora and nasolacrimal duct obstruction&#xD;
      have been reported as complications associated with the use of radioiodine, although studies&#xD;
      are not available to assess its true incidence through the systematic evaluation of patients.&#xD;
&#xD;
      It can be seen in routine practice that these patients would normally be referred for&#xD;
      ophthalmological examination only if a complaint, what happens in the process of OVL already&#xD;
      installed after the use of high doses of radioiodine. With the early evaluation of these&#xD;
      patients, the investigators focused on detecting the process of ongoing obstruction in order&#xD;
      to study interventions that prevent its final installation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lacrimal Apparatus Disease</condition>
  <arm_group>
    <arm_group_label>Thyroid carcinoma, Radioactive iodine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid carcinoma, without radioactive iodine therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radioiodine therapy</intervention_name>
    <description>Radioiodine therapy with NaI131</description>
    <arm_group_label>Thyroid carcinoma, Radioactive iodine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thyroid carcinoma&#xD;
&#xD;
          -  Previous thyroidectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential causes of dry eye (autoimmune diseases, contact lens wearers or drugs that&#xD;
             alter tear production, such as antihistamines and psychotropic)&#xD;
&#xD;
          -  Use of other anti-neoplastic, such as 5-fluorouracil and docetaxel, which can cause&#xD;
             epiphora and OVL&#xD;
&#xD;
          -  Lacrimal gland / ocular trauma&#xD;
&#xD;
          -  Radiation therapy for other diseases or radiotherapy of head and neck&#xD;
&#xD;
          -  Patients with diseases that alter the neural control of tear secretion, hormone&#xD;
             therapies, pterygium, Graves' disease with or without ophthalmopathy, blepharitis and&#xD;
             other conditions that may reduce tear production or result in rapid evaporation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzana Matayoshi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo; Ophthalmology Department</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 15, 2012</study_first_submitted>
  <study_first_submitted_qc>April 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Fabricio Lopes da Fonseca</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Iodine Radioisotopes</keyword>
  <keyword>Nasolacrimal Duct</keyword>
  <keyword>radiation effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Lacrimal Apparatus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

